TMEM132C is a transmembrane protein encoded on chromosome 12.3 with emerging roles in disease pathogenesis and clinical prognosis. Primary function: TMEM132C operates as a membrane-associated protein involved in cellular signaling pathways, particularly the PPARγ axis 1. Mechanism: The protein participates in synovial hyperplasia through PPARγ signaling regulation and influences DNA methylation-dependent gene expression in cancer contexts 1, 2. Disease relevance: TMEM132C shows significant associations across multiple pathologies. In cancer, differential methylation at the TMEM132C locus (cg03530754, cg04475027) serves as a diagnostic and prognostic marker in triple-negative breast cancer and estrogen-receptor-positive breast cancer 2, 3. In rheumatoid arthritis, TMEM132C drives synovial cell proliferation via PPARγ signaling 1. The gene associates with pulmonary function phenotypes in Asian populations 4, neurodevelopmental disorders as a regulatory bottleneck gene 5, and obesity risk through DNA methylation-mediated mechanisms following prenatal endocrine-disrupting chemical exposure 6. Clinical significance: TMEM132C variants (rs7296262 SNP) predict nausea susceptibility during opioid administration, with differential genotype effects between acute and chr12 exposure contexts 7. These findings establish TMEM132C as a pleiotropic biomarker with diagnostic and prognostic utility across oncologic, inflammatory, developmental, and pharmacogenetic domains.